Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • GDPR

    HemoScreen™ Hematology Analyzer for Point of Care, Receives FDA 510(k) Clearance


    News provided by

    PixCell Medical

    07 Nov, 2018, 12:00 IST

    Share this article

    Share this article


    - PixCell Medical's Point Of Care (POC)  blood analyzer is the first cartridge-based system to be FDA cleared, providing all 20 CBC parameters.

    - The HemoScreen™  should enable physicians to make more rapid and accurate decisions

    YOKNEAM, Israel, Nov. 7, 2018 /PRNewswire/ -- PixCell Medical announced today that The HemoScreen™ Hematology Analyzer received FDA 510(k) clearance, enabling commercialization in the USA.

    HemoScreen - Lab on a Cartridge
    HemoScreen - Lab on a Cartridge

    The HemoScreen™ is a miniature portable hematology analyzer that uses disposable cartridges; each cartridge includes all necessary reagents and is designed to accept a drop of blood taken from the finger. The operation of the device is exceptionally simple and requires minimal training or expertise.  Once the cartridge is inserted into the reader, the blood sample is automatically processed and analyzed within the cartridge and thus the concept is termed by the company "Lab On a Cartridge".

    "We are very excited to have reached this important milestone," says Dr. Avishay Bransky PixCell's CEO, "we have solved a decades-long problem of making a miniature POC CBC tester which is widely recognized as an unmet need."

    "The HemoScreen delivers lab accurate results and  would be especially useful at physicians' offices, ER, ICU, Oncology clinics and remote locations, " says Dr. Bransky.

    In contrast to existing solutions, the HemoScreen requires no maintenance or calibration which is extremely important in such settings.

    The HemoScreen™ should empower physicians to make validated, data-driven decisions: referring patients to the ER, prescribing antibiotics and other medication, ordering additional specific tests while reducing redundant tests and by that greatly improve patient care and workflow efficiency.

    The CBC is the most commonly performed lab test with nearly 2 billion tests per year in the USA and Europe. The CBC provides an important tool for evaluating patients' overall health and managing a wide range of disorders including infection, anemia and leukemia.

    Performance of the HemoScreen™ has been validated in numerous clinical studies in the USA and Europe, in different settings such as oncology, ICU and primary care.

    The HemoScreen™ employs patented technology based on microfluidics, machine vision and artificial intelligence (AI). Utilizing a new concept: Imaging Flow Cytometry where cells are flow focused into a single layer plane within a microfluidic chamber and their images are analyzed on the fly. This approach provides high repeatability and accuracy arising from flow and high resolution and sensitivity attained by imaging.

    Future assays based on the same platform technology are designed to detect the leading life-threatening diseases already at the POC i.e. cancer, infection, and heart failure.

    About PixCell Medical

    PixCell Medical  develops innovative POC diagnostic devices. The HemoScreen™ is designed to simplify blood testing, making it extremely accessible anywhere and to anyone. Future tests are expected to enable early detection of the most critical health threatening diseases including cancer, infection and heart failure.
    PixCell's technology is based on patented method called Viscoelastic Focusing and on a proprietary microfluidic based disposable.

    Contact:  
    Hanan Ben Asher, COO and BizDev
    Tel: +972-49593516
    [email protected]
    https://www.pixcell-medical.com/
    LinkedIn : https://www.linkedin.com/company/pixcell-medical-technologies/

    Modal title

    Also from this source

    PixCell Medical Expands into Canada Through Partnership with Inter Medico Following Health Canada Class III Licence for HemoScreen

    PixCell Medical Expands into Canada Through Partnership with Inter Medico Following Health Canada Class III Licence for HemoScreen

    PixCell Medical today announced its expansion into the Canadian market following the receipt of a Health Canada Class III Medical Device License for...

    HemoScreen Now Deployed Across More Than One-Third of NHS Mental Health Trusts, Supporting a New Integrated Diagnostics Model in Psychiatric Healthcare

    HemoScreen Now Deployed Across More Than One-Third of NHS Mental Health Trusts, Supporting a New Integrated Diagnostics Model in Psychiatric Healthcare

    More than one-third of NHS mental health trusts across the United Kingdom have now adopted PixCell Medical's HemoScreen point-of-care complete blood...

    More Releases From This Source

    Contact PR Newswire

    • +972-77-2005042
      from 8 AM - 11 PM IL

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Csezh
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italie
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +972-77-2005042
    from 8 AM - 11 PM IL
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.